EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Targeting Mast Cell Activation and MIF‐Mediated Remodelling Enhances Chemotherapy Response in Pancreatic Cancer

Libo Wang iD, Guangcong Shen, Guanpeng Xie, Zekun Li, Xiaoqing Ma, Mengyu Li, Ziyun Liu, Yadi Wang, Zongjing Lv, Qingxiao Fang, Huihui Sun, Ningning Zhao und 5 weitere

Advanced Science · 2025

DOI: 10.1002/advs.202509930 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Advanced Science, 2025. Verfasst von Libo Wang und 16 weiteren Autor:innen. Beteiligte Einrichtung: Pancreas Center, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, State Key Laboratory of Drug…. Hauptthemen laut MEDLINE: Macrophage Migration-Inhibitory Factors, Mast Cells, Pancreatic Neoplasms, Carcinoma, Pancreatic Ductal. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 56 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Key Research and Development Program of China, Tianjin Key Medical Discipline (Specialty) Construction Project, Postdoctoral Innovation Talent Support Program.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Neoadjuvant gemcitabine plus nab‐paclitaxel (AG) is increasingly applied in pancreatic ductal adenocarcinoma (PDAC), yet its effects on the tumor microenvironment (TME) remain incompletely defined. By integrating eight single‐cell RNA sequencing datasets and nine multicenter transcriptomic cohorts, the dual impact of AG in PDAC is delineated. AG shifts residual malignant cells from basal toward a more indolent classical phenotype and remodels the TME into a more heterogeneous and intricate landscape. Specifically, AG activates tumor‐associated mast cells (TAMCs), reprogrammes myofibroblastic cancer‐associated fibroblasts (myCAFs) into inflammatory CAFs (iCAFs), and enhances suppressive crosstalk between TAMCs, iCAFs, and T cells via the macrophage migration inhibitory factor (MIF) axis. Concurrently, AG reduces exhausted T cells and regulatory T cells while enriching cytotoxic natural killer T cells, reshaping the immune milieu in a manner potentially favorable for immunotherapy. In orthotopic and subcutaneous PDAC models, genetic ablation of TAMCs using Kit W‐sh mice or pharmacologic stabilization using sodium cromoglycate and the MIF antagonist ISO‐1 synergistically improves AG efficacy, with further benefit observed upon addition of anti‐PD‐1 therapy. These findings reveal a previously unrecognized mechanism of AG therapy‐induced immunosuppression and nominate TAMCs‐MIF signaling as a tractable target to optimize neoadjuvant strategies in PDAC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Macrophage Migration-Inhibitory FactorsMast CellsPancreatic NeoplasmsCarcinoma, Pancreatic DuctalIntramolecular OxidoreductasesHumansAnimalsMiceTumor MicroenvironmentPaclitaxelGemcitabineDeoxycytidineCell Line, TumorAlbumins

Stichwörter der Autor:innen

cancer‐associated fibroblastmacrophage migration inhibitory factorneoadjuvant chemotherapypancreatic ductal adenocarcinomatumor‐associated mast cell

Substanzen

Macrophage Migration-Inhibitory FactorsIntramolecular OxidoreductasesMIF protein, humanPaclitaxelGemcitabine130-nm albumin-bound paclitaxelDeoxycytidineAlbumins

Autor:innen und Institutionen

  • Pancreas Center, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, State Key Laboratory of Druggability Evaluation and Systematic Translational Medicine, Tianjin Key…

ORCID-Profile: Libo Wang, Tianxing Zhou

Förderung

  • National Key Research and Development Program of China
  • Tianjin Key Medical Discipline (Specialty) Construction Project
  • Postdoctoral Innovation Talent Support Program
  • China National Postdoctoral Program for Innovative Talents
  • China Postdoctoral Science Foundation
  • Science Technology Development Fund of the State Administration of Traditional Chinese medicine in Hebei Province
  • Tianjin Health Research Project
  • Tianjin Natural Science Foundation

Zitieren

APA

Wang, L., Shen, G., Xie, G., Li, Z., Ma, X., Li, M., Liu, Z., Wang, Y., Lv, Z., Fang, Q., Sun, H., Zhao, N., Yang, C., Zhou, T., Xie, Y., Yu, J., & Hao, J. (2025). Targeting Mast Cell Activation and MIF‐Mediated Remodelling Enhances Chemotherapy Response in Pancreatic Cancer. Advanced Science. https://doi.org/10.1002/advs.202509930

Vancouver

Wang L, Shen G, Xie G, Li Z, Ma X, Li M, et al. Targeting Mast Cell Activation and MIF‐Mediated Remodelling Enhances Chemotherapy Response in Pancreatic Cancer. Advanced Science. 2025. doi:10.1002/advs.202509930

BibTeX
@article{Wang2025,
  author = {Wang, Libo and Shen, Guangcong and Xie, Guanpeng and Li, Zekun and Ma, Xiaoqing and Li, Mengyu and Liu, Ziyun and Wang, Yadi and Lv, Zongjing and Fang, Qingxiao and Sun, Huihui and Zhao, Ningning and Yang, Chao and Zhou, Tianxing and Xie, Yongjie and Yu, Jun and Hao, Jihui},
  title = {Targeting Mast Cell Activation and MIF‐Mediated Remodelling Enhances Chemotherapy Response in Pancreatic Cancer},
  journal = {Advanced Science},
  year = {2025},
  doi = {10.1002/advs.202509930}
}
Kostenlos starten →